(Press-News.org) SCOTTSDALE, Ariz. -- An international research team led by Mayo Clinic oncologists has found a new way to identify and possibly stop the progression of many late-stage cancers, including bladder, blood, bone, brain, lung and kidney.
MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic News Network.
The precision medicine study appears online in Oncogene and focuses on kidney cancer and its metastases. Recent studies of the same epigenomic fingerprint in other cancers suggest a common pathway that could help improve the diagnosis and treatment of advanced disease across a wide variety of cancer types.
"If you think of late-stage cancer as a runaway car, most of our drugs take a shot at a tire here and there, but sometimes they miss and often they can't stop it entirely," says Thai Ho, M.D., Ph.D., a Mayo Clinic oncologist and lead author of the study. "We believe we have identified a mechanism that seizes the cancer's biological engine and could potentially stop it in its tracks."
The new approach zeroes in on an epigenomic fingerprint in metastatic disease, in which the body often misinterprets a healthy genetic blueprint, producing toxic cells that run afoul of the body's normal functions.
Dr. Ho and his colleagues are currently validating a test based on the newly identified epigenomic fingerprint, called H3K36me3 loss, which could help providers identify more aggressive cancers or find the best drug for the individual patient to further personalize medical care.
"This paper is the first report we know of translating this fingerprint into patient tissues, and efforts are ongoing to expand this to tumors beyond kidney cancer," says Dr. Ho.
The test and a potential treatment are based on an emerging discipline of medical research called epigenomics, the complex biological process through which individual cells read their genetic blueprints and then determine what type of tissue to become.
Dr. Ho offers the example of honeybees as among the starkest examples of how epigenomics affects cellular function and an organism's fate.
Throughout their life spans, all bees in a hive share the same DNA sequence. But some bees become drones, others sterile female workers, and still others the queen. Much of this differentiation can be attributed to epigenomics, says Dr. Ho.
In feeding a larval honeybee with copious amounts of a richly nutritious secretion called royal jelly, the larva will eventually develop into a queen. Chemicals present in the royal jelly, but absent in nectar and pollen, are thought to activate entirely different parts of the same bee genome -- converting one larva into the queen while others, such as workers and drones, are much smaller and have shorter life spans. Similarly, cancers often subvert a cell's normal epigenomic mechanisms to become more aggressive.
INFORMATION:
The study represents a collaborative effort from the Mayo Clinic Center for Individualized Medicine, spanning at all three Mayo sites: Mayo Clinic in Arizona, Mayo Clinic in Florida, and Mayo Clinic in Minnesota. Scientists and physicians at MD Anderson Cancer Center, Texas A&M University, Baylor College of Medicine, Van Andel Research Institute and National Cancer Centre Singapore contributed to this two-year study.
Funding comes from the National Institutes of Health, Mayo Clinic Center for Individualized Medicine and generous benefactors of Mayo Clinic.
Co-authors of the study are: In Young Park, Ph.D., and Cheryl Walker, Ph.D., both of Texas A&M University; Hao Zhao, Ph.D., Pan Tong, Ph.D., Anh Hoang, Pheroze Tamboli, M.D., Wei Qiao, Nizar Tannir, M.D., Jing Wang, Ph.D., Mien-Chie Hung, Ph.D., and Eric Jonasch, M.D., of MD Anderson Cancer Center; Karl Dykema, of Van Andel Research Institute; Bin Tean Teh, M.D., Ph.D., of Van Andel Research Institute and National Cancer Centre Singapore; Federico Monzon, M.D., of Baylor College of Medicine; and Mia Champion, Ph.D., Huihuang Yan, Ph.D., Alexander Parker, Ph.D., Richard Joseph, M.D., Erik Castle, M.D., and Rafael Nunez Nateras, M.D., of Mayo Clinic.
About the Mayo Clinic Center for Individualized Medicine
The Mayo Clinic Center for Individualized Medicine is home to the Individualized Medicine Clinic, the world's first integrated, multidisciplinary genomics clinic, serving patients with advanced cancer and diagnostic dilemmas. The center discovers and integrates the latest in genomic, molecular and clinical sciences into personalized care for each Mayo Clinic patient. Visit http://mayoresearch.mayo.edu/center-for-individualized-medicine/ for more information.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic and http://newsnetwork.mayoclinic.org/.
The best sparkling wines take months to ferment to perfection. In recent years, many winemakers have turned to commercial yeast products to give this process a boost. How they ultimately affect bubbly has been an open question, but now scientists have stepped in to find out. They report their findings in ACS' Journal of Agricultural and Food Chemistry.
When sparkling wine is made, yeast cells burst open in a process called autolysis. This releases a special kind of protein called mannoproteins that, in still wines (the non-bubbly kind), can reduce astringency and bitterness, ...
Researchers from Cardiff University have pioneered a new technique that will enable scientists to precisely pinpoint the areas on an enzyme that help to speed up chemical reactions.
By labelling certain segments of an enzyme with heavy isotopes, the researchers have found that 'heavy' and 'light' versions of enzymes have different catalytic properties, allowing them to determine which regions are linked to specific functions.
It is hoped this precise pinpointing may shed light on why enzymes are much more efficient at speeding up chemical reactions compared to man-made ...
LOS ANGELES -- In two ancillary studies of two multi-center international clinical trials led by the University of Southern California (USC) Eye Institute, the injectable drug ocriplasmin appears to improve vision among patients suffering from symptomatic vitreomacular adhesion (VMA), a condition related to the aging eye that could cause permanent vision loss if left untreated.
'These are the first large studies that document patient-reported visual improvement after injection of ocriplasmin for symptomatic VMA,' said Rohit Varma, M.D., M.P.H., director of the USC Eye ...
Lisbon, 17 June 2015: An IVF technique which freezes all embryos generated in an initial treatment cycle and transfers them in a later cycle as freeze-thawed embryos does not improve outcome as some studies have suggested.
Results of the study, performed at the Instituto Valenciano de Infertilidad (IVI) clinic in Valencia, Spain, are presented today at the ESHRE Annual Meeting by Dr Ernesto Bosch, Medical Director of IVI Valencia, Spain.
As background to his report, Dr Bosch noted that several studies have found improved outcomes in IVF when all embryos are electively ...
Nyon, Switzerland - June 17, 2015 -- An International Osteoporosis Foundation (IOF) Working Group on Skeletal Rare Diseases has published a new classification of rare genetic metabolic bone disorders (RGMBDs) according to their metabolic pathogenesis.
Skeletal Rare Diseases such as osteogenesis imperfecta, juvenile Paget's disease or osteopetrosis, are only three of the more than 400 developmental abnormalities of the skeletal system that affect patients worldwide. Although rare, these 'orphan' diseases have a very serious, and often devastating, impact on the lives ...
Scientists at the Ruhr-Universität Bochum established a mouse model for the human disease SCA6. SCA6 is characterised by movement deficits and caused by similar genetic alterations as Chorea Huntington. The mouse model will be used to investigate the disease mechanisms. Experiments suggest that an impairment of eye blink conditioning could be an early disease symptom. The team from the Department of Zoology and Neurobiology published their data in the Journal of Neuroscience; the work was highlighted by the editor's commentary.
Spinocerebellar ataxia 6: structural ...
This news release is available in German. Ragweed (Ambrosia artemisiifolia) - an otherwise unremarkable plant - produces pollen that can trigger strong allergic reactions such as asthma even in very small quantities. Scientists from Technische Universität München (TUM) and Helmholtz Zentrum München have now published a joint study showing that the substance previously identified as the major allergen only induces such a vigorous allergic response in combination with the adenosine also present in the pollen.
Ragweed only started to become widespread ...
A group of researchers at Chalmers University of Technology have managed to print and dry three-dimensional objects made entirely by cellulose for the first time with the help of a 3D-bioprinter. They also added carbon nanotubes to create electrically conductive material. The effect is that cellulose and other raw material based on wood will be able to compete with fossil-based plastics and metals in the on-going additive manufacturing revolution, which started with the introduction of the 3D-printer.
3D printing is a form of additive manufacturing that is predicted to ...
Astronomers have long theorised the existence of a first generation of stars -- known as Population III stars -- that were born out of the primordial material from the Big Bang [1]. All the heavier chemical elements -- such as oxygen, nitrogen, carbon and iron, which are essential to life -- were forged in the bellies of stars. This meansthat the first stars must have formed out of the only elements to exist prior to stars: hydrogen, helium and trace amounts of lithium.
These Population III stars would have been enormous -- several hundred or even a thousand times more ...
Scientists have developed a new tissue 'scaffold' technology that could one day enable the engineering of large organs.
Research led by the Universities of Bristol and Liverpool has shown that it is possible to combine cells with a special scaffold to produce living tissue in the laboratory. It is hoped this can then be implanted into patients as a way of replacing diseased parts of the body.
Until now, the approach has generally been limited to growing small pieces of tissue, as larger dimensions reduce the oxygen supply to the cells in the centre.
A team of ...
